Depletion of estrogen stores in the endometrium significantly improves the response of endometrial cancer to treatment with inhibitors of poly (ADP-ribose) -polymerase (PARP inhibitors).

Preparations of this group in vitro demonstrated antitumor activity against all endometrial cancer cell lines, but their in vivo efficacy remains unexplored.

Using laboratory mice, researchers from California experimentally induced a "loss" of the PTEN gene (phosphatase with a double substrate specificity) that occurs with 80% of endometrial tumors.

This, in turn, gave impetus to the development of cancer.

The rodents were then treated with the parp-inhibitor olaparib at the normal level of estrogen in the tissues, and also after the experimental removal of estrogen from the endometrium.

Therapy worked only in the absence of estrogen.

According to researchers in the online edition of Molecular Cancer Therapeutics, this "points to the essential role of the hormone in maintaining the viability of cancer cells".

"The difference in response to treatment was very large. It was like day and night, "commented the researcher Sanaz Memarzadeh of the University of California in Los Angeles.

Scientists hope to soon reach clinical trials, which will confirm the effectiveness of the combination of PARP-inhibitors and estrogen-modulating drugs.

medbe. en.

Keywords:.